Eclitasertib is under clinical development by Denali Therapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eclitasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eclitasertib overview
DNL-758 (SAR-443122) is under development for the treatment of peripheral inflammatory disease, psoriasis, rheumatoid arthritis, cutaneous lupus erythematosus and ulcerative colitis. It is administered through oral route. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase1 (RIPK1).
It was also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Denali Therapeutics overview
Denali Therapeutics is a clinical-stage biopharmaceutical company that develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. The company’s proprietary technology platform, which develops brain-penetrant therapies based on enzyme transport vehicle, antibody transport vehicle, protein transport vehicleand oligonucleotide transport vehicle. Its pipeline products include Iduronate 2-sulfatase, LRRK2, Progranulin, Sulfamidase, Alpha-L-iduronidase, eIF2B and RIPK1 (Peripheral). The company’s pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, lysosomal storage disorder disease, neurodegeneration, amyotrophic lateral sclerosis and other indications. Denali Therapeutics is headquartered in San Francisco, California, the US.
For a complete picture of Eclitasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
